对比增强乳腺X线摄影评估HER2阳性浸润性乳腺癌伴导管原位癌成分
本研究回顾性纳入2013—2021年62例HER2阳性浸润性乳腺癌伴导管原位癌成分患者,由两名放射科医师独立重新评估对比增强乳腺X线摄影(CEM),并由乳腺病理医师重新评估组织病理标本,旨在探讨CEM上导管原位癌成分的影像表现。结果显示,在原发性手术组(n=45)中,CEM检出浸润性肿瘤外35个导管原位癌成分中的27个(77.1%);非肿块强化(NME)对导管原位癌直径的预测优于可疑钙化(ICC=0.65 vs ICC=0.43),可疑钙化的观察者间一致性优于NME(κ=0.81 vs κ=0.47)。
要点
- CEM可检出浸润性肿瘤外77.1%(27/35)的导管原位癌成分,对手术决策有参考价值。
- NME预测导管原位癌直径的ICC为0.65,优于可疑钙化的ICC=0.43。
- 可疑钙化观察者间一致性κ=0.81,优于NME的κ=0.47。
核心结论
- CEM能检出浸润性肿瘤外77.1%的导管原位癌成分;NME是预测导管原位癌直径最准确的征象,但观察者间一致性有待提高。
研究设计与样本
- 回顾性研究,纳入2013—2021年62例HER2阳性浸润性乳腺癌伴导管原位癌成分且接受CEM的女性患者,由两名放射科医师独立重新评估CEM图像,并由一名乳腺病理医师重新评估组织病理标本。
关键影像表现/征象
- CEM上与导管原位癌相关的表现:可疑钙化占27.4%,NME占16.1%,两者同时存在占27.4%,无相关表现占29.0%。
- 原发性手术组(n=45)中,CEM检出浸润性肿瘤外35个导管原位癌成分中的27个(77.1%)。
诊断标准与关键数值
- NME预测导管原位癌直径的ICC=0.65,可疑钙化的ICC=0.43。
- 可疑钙化检出的观察者间一致性κ=0.81,NME的κ=0.47。
- 可疑钙化与NME测量尺寸的观察者间信度相当,ICC分别为0.89与0.80。
临床应用与阅片要点
- 阅片时需同时关注可疑钙化与NME,两者同时存在占27.4%,无相关表现占29.0%。
- NME对导管原位癌直径的预测较可疑钙化更准确(ICC=0.65 vs 0.43),但观察者间一致性较低(κ=0.47)。
- 可疑钙化的检出观察者间一致性较高(κ=0.81),可作为稳定识别的征象。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: A DCIS component can be present accompanying HER2+ invasive breast cancer (IBC) in approximately 57 % of patients. Until now, no contrast-enhanced mammography (CEM) studies have investigated the detection of a DCIS component, which is important for surgical decision-making. This study aimed to investigate imaging findings of a DCIS component in HER2+ IBC on CEM.
METHODS: Women with HER2+ IBC with a DCIS component that underwent CEM between 2013-2021 were included. Two independent radiologists retrospectively reassessed CEM exams, and a breast pathologist reassessed histopathology specimen. The percentage and extent of suspicious calcifications and non-mass enhancement (NME) on CEM, and interobserver agreement between radiologists was determined. In the primary surgery group, the detection rate of DCIS outside of the invasive tumor was determined, and maximum diameter of imaging findings was compared to histopathology.
RESULTS: Sixty-two patients were included. CEM showed suspicious calcifications (27.4 %), NME (16.1 %), both (27.4 %) or no findings (29.0 %), related to DCIS. In the primary surgery group (n = 45), CEM detected 27 of 35 DCIS components present outside of the invasive tumor (77.1 %). NME was a better predictor for DCIS diameter (ICC = 0.65) compared to suspicious calcifications (ICC = 0.43). Inter-observer agreement on detection of imaging findings was better for suspicious calcifications (κ = 0.81) compared to NME (κ = 0.47), while reliability between size measurements was comparable (ICC = 0.89 versus ICC = 0.80, respectively).
CONCLUSION: CEM was able to detect 77.1% of DCIS present outside of the invasive tumor. NME is the most accurate predictor of DCIS diameter, but requires improvements regarding inter-observer agreement.
引用
- Ploumen RAW, Mommertz JA, Minis-Rutten IJG, et al. Evaluation of a ductal carcinoma in situ component accompanying HER2-positive invasive breast cancer on contrast-enhanced mammography. Eur J Radiol. 2025. PMID: 40090048. doi:10.1016/j.ejrad.2025.112040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。